Department of Immunology, PSL Research University, INSERM U932, Institut Curie, 26, rue d'Ulm, 75005 Paris, France.
Department of Internal Clinical Sciences, Anaesthesiology and Cardiovascular Sciences, Sapienza Università di Roma, 00161 Rome, Italy.
Int J Mol Sci. 2021 Jul 28;22(15):8068. doi: 10.3390/ijms22158068.
CD39 is an enzyme which is responsible, together with CD73, for a cascade converting adenosine triphosphate into adenosine diphosphate and cyclic adenosine monophosphate, ultimately leading to the release of an immunosuppressive form of adenosine in the tumor microenvironment. Here, we first review the environmental and genetic factors shaping CD39 expression. Second, we report CD39 functions in the T cell compartment, highlighting its role in regulatory T cells, conventional CD4 T cells and CD8 T cells. Finally, we compile a list of studies, from preclinical models to clinical trials, which have made essential contributions to the discovery of novel combinatorial approaches in the treatment of cancer.
CD39 是一种酶，与 CD73 一起负责一系列反应，将三磷酸腺苷转化为二磷酸腺苷和环磷酸腺苷，最终导致肿瘤微环境中免疫抑制形式的腺苷释放。在这里，我们首先回顾了影响 CD39 表达的环境和遗传因素。其次，我们报告了 CD39 在 T 细胞区室中的功能，重点介绍了其在调节性 T 细胞、常规 CD4 T 细胞和 CD8 T 细胞中的作用。最后，我们整理了一系列研究，从临床前模型到临床试验，这些研究对发现癌症治疗的新组合方法做出了重要贡献。
